Atossa Genetics is a clinical-stage pharmaceutical company focused on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its patented intraductal microcatheters that deliver pharmaceuticals through the breast milk ducts. Atossa has initiated a Phase 2 clinical study using its microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer.

Oral endoxifen is the Company's second development program. Endoxifen is an active metabolite of tamoxifen, an FDA approved drug for breast cancer patients to prevent recurrence as well as new breast cancer.

Atossa Genetics is passionate about improving breast health and the overall well-being and health of women and men.

Employee Rating

2.6More
TypePublic
HQSeattle, US
Founded2009
Size (employees)18 (est)
Websiteatossagenetics.com
Atossa Genetics was founded in 2009 and is headquartered in Seattle, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Atossa Genetics

Steven C. Quay

Steven C. Quay

Chairman of the Board and Chief Executive Officer
Kyle Guse

Kyle Guse

Chief Financial Officer, General Counsel and Secretary
Janet Rose Rea

Janet Rose Rea

Senior Vice President, Regulatory, Quality, Clinical Affairs
Show more

Atossa Genetics Office Locations

Atossa Genetics has an office in Seattle
Seattle, US (HQ)
4105 E Madison St
Show all (1)
Report incorrect company information

Atossa Genetics Financials and Metrics

Atossa Genetics Revenue

Atossa Genetics's revenue was reported to be $1.76 k in FY, 2015
USD

Net income (Q2, 2018)

(4.1m)

EBIT (Q2, 2018)

(4.1m)

Market capitalization (14-Dec-2018)

6.9m

Closing stock price (14-Dec-2018)

1.2

Cash (30-Jun-2018)

15.2m
Atossa Genetics's current market capitalization is $6.9 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

632.6k1.8k

Cost of goods sold

345.5k132.4k

Gross profit

287.0k(130.7k)

Gross profit Margin, %

45%(7432%)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q2, 2016Q3, 2016Q1, 2017Q2, 2018

Revenue

76.6k24.1k9.9k3.4k2.7m772.2k

Cost of goods sold

25.9k1.9m313.4k

Gross profit

50.7k839.4k458.8k

Gross profit Margin, %

66%31%59%
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Cash

6.3m3.7m3.0m7.2m

Accounts Receivable

139.1k

Current Assets

7.4m4.3m3.3m7.9m

Total Assets

12.0m6.2m4.1m8.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q2, 2016Q3, 2016Q1, 2017Q2, 2018

Cash

7.7m16.6m14.3m11.4m11.4m7.8m1.2m4.4m1.2m15.2m

Accounts Receivable

299.3k91.4k48.2k29.2k2.0m1.1m

Inventories

1.9k45.9k101.3k170.9k

Current Assets

8.6m17.7m14.7m11.7m13.8m9.5m1.5m4.6m1.5m16.4m
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Net Income

(10.8m)(15.8m)(6.4m)(8.1m)

Depreciation and Amortization

472.9k272.6k303.5k129.0k

Inventories

9.3k

Accounts Payable

301.4k(560.1k)80.6k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q2, 2016Q3, 2016Q1, 2017Q2, 2018

Net Income

(8.0m)(2.4m)(5.6m)(8.8m)(6.5m)(10.8m)(4.0m)(3.8m)(1.7m)(6.0m)

Depreciation and Amortization

350.5k125.1k252.9k381.0k170.8k249.7k152.6k227.4k40.1k17.8k

Inventories

(1.9k)(45.9k)(61.6k)(131.1k)

Accounts Payable

542.0k191.1k(13.8k)326.8k(531.7k)(617.1k)132.6k(143.7k)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Atossa Genetics Online and Social Media Presence

Embed Graph
Report incorrect company information

Atossa Genetics News and Updates

Thinking about buying stock in Atossa Genetics, Cronos Group, New Age Beverages Co, Tesaro Inc. or 22nd Century Group Inc.?

NEW YORK, Dec. 4, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATOS, CRON, NBEV, TSRO, and XXII. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ...

Atossa Genetics Completes Enrollment in Phase 2 Study of Topical Endoxifen in Women with Mammographic Breast Density

SEATTLE, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, has completed enrollment in its Phase 2 study of Atossa’s proprietary Topical …

Atossa Genetics to Host Conference Call to Announce Preliminary Results from Male Phase 1 Study of Topical Endoxifen Thursday, September 13, 2018 at 10 am EDT

SEATTLE, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, will host a conference call on September 13, 2018 at 10 am EDT to discuss pre…
Show more
Report incorrect company information

Atossa Genetics Blogs

Atossa Genetics Contracts with Additional Manufacturer of Endoxifen

SEATTLE, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that is has added Alchem Laboratori…

Atossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program

SEATTLE, July 18, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it is advancing its intraducta…

Atossa Genetics Company Life and Culture

Report incorrect company information

Atossa Genetics Frequently Asked Questions

  • When was Atossa Genetics founded?

    Atossa Genetics was founded in 2009.

  • Who are Atossa Genetics key executives?

    Atossa Genetics's key executives are Steven C. Quay, Kyle Guse and Janet Rose Rea.

  • How many employees does Atossa Genetics have?

    Atossa Genetics has 18 employees.

  • Who are Atossa Genetics competitors?

    Competitors of Atossa Genetics include Galectin Therapeutics, Stemline Therapeutics and Cellular Biomedicine Group.

  • Where is Atossa Genetics headquarters?

    Atossa Genetics headquarters is located at 4105 E Madison St, Seattle.

  • Where are Atossa Genetics offices?

    Atossa Genetics has an office in Seattle.

  • How many offices does Atossa Genetics have?

    Atossa Genetics has 1 office.